Stifel Nicolaus downgraded shares of GTX (NASDAQ:GTXI) from a buy rating to a hold rating in a report published on Friday morning, The Fly reports.

Several other equities analysts also recently weighed in on GTXI. BidaskClub upgraded GTX from a hold rating to a buy rating in a report on Wednesday, May 30th. Zacks Investment Research upgraded GTX from a sell rating to a hold rating in a report on Tuesday, July 17th. Finally, Robert W. Baird downgraded GTX from an outperform rating to a neutral rating and set a $17.00 price target for the company. in a report on Friday. Five research analysts have rated the stock with a hold rating, The stock has a consensus rating of Hold and an average target price of $31.00.

Shares of NASDAQ:GTXI opened at $1.80 on Friday. GTX has a 1-year low of $1.66 and a 1-year high of $25.60.

GTX (NASDAQ:GTXI) last issued its quarterly earnings results on Tuesday, August 14th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43). research analysts anticipate that GTX will post -1.85 earnings per share for the current fiscal year.

In other GTX news, Chairman Robert James Wills acquired 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 26th. The shares were bought at an average cost of $16.75 per share, with a total value of $83,750.00. Following the completion of the transaction, the chairman now directly owns 137,344 shares of the company’s stock, valued at approximately $2,300,512. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Diane C. Young sold 2,049 shares of the stock in a transaction on Monday, July 16th. The shares were sold at an average price of $14.70, for a total value of $30,120.30. The disclosure for this sale can be found here. Company insiders own 41.20% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio purchased a new stake in shares of GTX during the second quarter valued at $163,000. GSA Capital Partners LLP purchased a new stake in shares of GTX during the first quarter valued at $197,000. Element Capital Management LLC purchased a new stake in shares of GTX during the first quarter valued at $234,000. Northern Trust Corp boosted its position in shares of GTX by 23.9% during the first quarter. Northern Trust Corp now owns 18,705 shares of the biopharmaceutical company’s stock valued at $332,000 after buying an additional 3,605 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of GTX during the second quarter valued at $296,000. 28.38% of the stock is currently owned by institutional investors.

About GTX

GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.

Featured Article: Book Value Per Share – BVPS

The Fly

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with's FREE daily email newsletter.